July 30, 2024 Bulletins SENATE BILL 273, IMPLEMENTATION – SUBMISSION OF HEALTH INSURANCE POLICIES FOR COMPLIANCE REVIEW BULLETIN 2024-013 Senate Bill 273, Parity for Coverage of Mental Health and Substance Use Disorder (MH/SUD) Services (SB273) was enacted in the 2023 New Mexico legislative session and became effective on January 1, 2024. SB273 amended certain sections of, and added other sections to, the New Mexico Insurance Code included in Chapter 59A, Articles 22B (Prior Authorization), 23 (Group and Blanket Health Insurance Contracts), 23E (Health Insurance Portability Act), 46 (Health Maintenance Organization Law), and 47 (Nonprofit Health Care Plan Law). The Office of Superintendent of Insurance (OSI), through its Life and Health Division, will enforce the provisions of SB273.Through its compliance review required by SB273, OSI will review claims processing, provider reimbursement procedures, network adequacy, provider reimbursement rate adequacy, utilization management, level of care determinations and medication coverage to ensure access to MH/SUD services and providers, including parity with medical and surgical services. Additionally, the OSI shall ensure that a health care plan complies with federal and state laws, rules and regulations applicable to coverage for MH/SUD services.SENATE BILL 273, IMPLEMENTATION – SUBMISSION OF HEALTH INSURANCE POLICIES FOR COMPLIANCE REVIEW
June 26, 2026 Bulletins MEDICAL MALPRACTICE PREMIUM REDUCTION AMENDED BULLETIN 2026-010: The New Mexico State Legislature appropriated $5 million to the New Mexico Office of Superintendent of Insurance (OSI) to address medical malpractice insurance costs for individual providers. The appropriation was part of a supplemental appropriation package passed in 2025. This one-time appropriation directs OSI to provide a premium subsidy for private medical malpractice insurance policies. […] Read More
June 12, 2026 Announcements NOTICE OF PRESCRIPTION DRUG PRICE TRANSPARENCY ANNUAL MEETING The Office of the Superintendent of Insurance will hold its annual public meeting to present and discuss the findings and recommendations contained in the 2025 Prescription Drug Price Transparency legislative report. The purpose of this meeting is to inform the public of the report’s contents and to provide an opportunity for public comments and questions. […] Read More